Clarification technologies for monoclonal antibody manufacturing processes: Current state and future perspectives

Area of Science:

• Biotechnology
• Bioprocessing
• Chemical Engineering

Background:

• Rising demand for antibody biopharmaceuticals necessitates increased cell culture productivity.
• Higher cell densities and longer culture times lead to increased process and product impurities.
• Biopharmaceutical industry trends show increased productivity and niche indications, demanding advanced manufacturing strategies.

Purpose of the Study:

• To review recent advancements in clarification technologies for mammalian cell cultures producing monoclonal antibodies.
• To identify and discuss challenges associated with implementing these new generation clarification technologies.
• To explore the potential of flocculation and precipitation as viable solutions for antibody purification bottlenecks.

Main Methods:

• Review of recent literature on novel clarification technologies.
• Analysis of technical challenges including platform suitability, robustness, cost, toxicity, and clearance.
• Case study examination of implementation strategies for new clarification methods.

Main Results:

• Flocculation and precipitation are emerging as promising clarification technologies for antibody manufacturing.
• Several technical hurdles remain, including process validation, scalability, and impurity removal efficiency.
• Successful implementation requires careful consideration of cost-effectiveness and product safety.

Conclusions:

• New generation clarification technologies show potential to address bottlenecks in antibody biopharmaceutical production.
• Addressing challenges related to robustness, cost, and toxicity is crucial for widespread adoption.
• Further development and case studies are necessary to establish these methods as platform applications.